Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Office of Compliance appoints policy director

Executive Summary

Deborah Autor named CDER Office of Compliance Associate Director for Compliance Policy; she was Department of Justice lead counsel in the case that won FDA its right to collect "disgorgement fees" for GMP violations (1"The Pink Sheet" Oct. 23, 2000, p. 4). In her newly created position, Autor reports to Office of Compliance Acting Director David Horowitz...

You may also be interested in...



CDER Compliance Office Head Horowitz Is Former Associate Chief Counsel

The Center for Drug Evaluation & Research Office of Compliance will be led by a director with experience in litigation and policy development rather than a background in the field offices.

Pfizer Eyes EU Pegfilgrastim Roll-Out By 1 April As US Launch Is Confirmed

Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.

Samsung Bioepis Opens New HQ To Drive Next-Generation Biosimilars

With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel